Calithera Biosciences, Inc.

OTCPK:CALA Stock Report

Market Cap: US$1.9k

Calithera Biosciences Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Calithera Biosciences's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Dec 2022

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Oct 03

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Calithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.
Seeking Alpha • Aug 29

Calithera rises 8% after HC Wainwright upgrades rating to buy

Calithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.
Analysis Article • Aug 17

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 17

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Aug 27

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 03

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.
Analysis Article • May 02

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 10

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...
Analysis Article • Jan 17

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...
Analysis Article • Dec 13

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Revenue & Expenses Breakdown

How Calithera Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:CALA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 220-21140
30 Sep 220-841551
30 Jun 227-851951
31 Mar 2210-1071951
31 Dec 2110-1152151
30 Sep 2110-68220
30 Jun 213-80200
31 Mar 210-86210
31 Dec 200-90200
30 Sep 200-89190
30 Jun 200-87180
31 Mar 200-91170
31 Dec 190-90170
30 Sep 190-88150
30 Jun 190-86140
31 Mar 1917-65140
31 Dec 1822-55130
30 Sep 1830-46130
30 Jun 1837-33130
31 Mar 1827-35130
31 Dec 1726-28130
30 Sep 1719-26120
30 Jun 1711-29110
31 Mar 174-34110
31 Dec 160-38110
30 Sep 160-37106
30 Jun 160-371013
31 Mar 160-34918
31 Dec 150-3390

Quality Earnings: Insufficient data to determine if CALA has high quality earnings.

Growing Profit Margin: Insufficient data to determine if CALA's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CALA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare CALA's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if CALA's earnings growth over the past year exceeded the Biotechs industry average.

Return on Equity

High ROE: CALA has a negative Return on Equity (0%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 09:21
End of Day Share Price 2026/07/01 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Calithera Biosciences, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mohit BansalCitigroup Inc
Michael KingCitizens JMP Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.